For the next two decades, our group and numerous others continued to preclinically investigate molecular pathways conferring the neuroprotective and anti-neurodegenerative benefits of incretin mimetics [30,31,32,33,34,35], as well as testing numerous formulations of incretin-based receptor agonists in neurodegenerative disease models [36,37,38,39]. Here, GCG is linked to neurodegenerative disease.